News &amp; Updates

Among patients with viral hepatitis-related cirrhosis who sustained non-bleeding decompensating events, the use of non-selective beta blockers is associated with lower mortality, as shown in a study.

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

Original New Drug Application Approvals by US FDA (1-15 June 2026)

New drug applications approved by US FDA as of 1-15 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 June 2026)

Inhaled nitrous oxide provides efficacious analgesia for outpatient hysteroscopic procedures

The use of inhaled nitrous oxide during outpatient operative hysteroscopy helps reduce intraprocedural pain and promote successful completion of procedures, resulting in increased patient satisfaction, according to a study.

Inhaled nitrous oxide provides efficacious analgesia for outpatient hysteroscopic procedures

Dual immune checkpoint blockade delivers encouraging survival benefit in LACC

Neoadjuvant nivolumab plus ipilimumab followed by chemoradiation and maintenance nivolumab yields high survival rates in locally advanced cervical cancer (LACC), according to final survival data from the phase II COLIBRI-1 trial.

Dual immune checkpoint blockade delivers encouraging survival benefit in LACC

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

In hepatitis B e antigen-negative (HBeAg) patients, the last antiviral agent used prior to end of therapy (EOT) appears predictive of the timing of clinical relapse, according to a study. An entecavir-switching strategy may prevent relapse and reduce hepatitis flare and its severity within 24 weeks after EOT.

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

Pulse steroid therapy tied to bone turnover marker suppression, but not BMD loss

Pulse intravenous methylprednisolone does not induce short-term loss of lumbar spine or hip bone mineral density (BMD), reports a Singapore study. However, it does suppress bone turnover markers, suggesting early effects on bone remodelling that are not captured by BMD alone.

Pulse steroid therapy tied to bone turnover marker suppression, but not BMD loss

Anticoagulants up risk of bleeding after esophageal dilation procedure

Patients taking anticoagulant medications at the time of esophageal dilation are at increased risk of experiencing gastrointestinal bleeding after the procedure, suggests a study.

Anticoagulants up risk of bleeding after esophageal dilation procedure

Pooled analysis validates iptacopan safety for PNH

A pooled analysis presented at EHA 2026 demonstrates the long-term safety of the oral proximal complement inhibitor iptacopan in the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Pooled analysis validates iptacopan safety for PNH

6-session exercise programme brings sustained benefits to knee OA patients awaiting TKR